Oncology / Haematology
A RANDOMIZED PHASE III STUDY OF DURATION OF ANTI-PD-1 THERAPY IN METASTATIC MELANOMA
|Trial Name: STOP-GAP||PI: Dr Oliver Klein|
Who can take part:
- Histologically confirmed melanoma that is unresectable / metastatic (stage III or stage IV).
- Patients must have evidence of unresectable / metastatic disease, that is considered evaluable by the investigator and can be followed, but measurable disease is not mandatory
- Patients with brain metastases are allowed, provided they are stable
- Patients not willing to stop anti-PD-1 therapy, if randomized to the intermittent arm.
For further information please contact Ellen – 9784-8562
Non-drug Phase 1 Phase 2 Phase 3 Phase 4